Early, preemptive blockade of nerve growth factor (NGF)/tropomyosin receptor kinase A (TrkA) attenuates tumor-induced nerve sprouting and bone cancer pain. A critical unanswered question is whether late blockade of NGF/TrkA can attenuate cancer pain once NGF-induced nerve sprouting and neuroma formation has occurred. By means of a mouse model of prostate cancer-induced bone pain, anti-NGF was either administered preemptively at day 14 after tumor injection when nerve sprouting had yet to occur, or late at day 35, when extensive nerve sprouting had occurred. Animals were humanely killed at day 70 when, in vehicle-treated animals, significant nerve sprouting and neuroma formation was present in the tumorbearing bone. Although preemptive and sustained administration (days 14-70) of anti-NGF more rapidly attenuated bone cancer nociceptive behaviors than late and sustained administration (days 35-70), by day 70 after tumor injection, both preemptive and late administration of anti-NGF significantly reduced nociceptive behaviors, sensory and sympathetic nerve sprouting, and neuroma formation. In this model, as in most cancers, the individual cancer cell colonies have a limited half-life because they are constantly proliferating, metastasizing, and undergoing necrosis as the parent cancer cell colony outgrows its blood supply. Similarly, the sensory and sympathetic nerve fibers that innervate the tumor undergo sprouting at the viable/leading edge of the parent tumor, degenerate as the parent cancer cell colony becomes necrotic, and resprout in the viable, newly formed daughter cell colonies. These results suggest that preemptive or late-stage blockade of NGF/TrkA can attenuate nerve sprouting and cancer pain. Ó
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Introduction
In 2010, over 12 million cancer cases (excluding nonmelanoma skin cancer) and 7.6 million cancer deaths occurred worldwide [21] . Improvements in the detection and treatment of most cancers have increased survival rates so that even patients diagnosed with metastatic cancer can survive years to decades beyond their initial diagnosis [22] . For many patients, pain is not only the first sign of cancer, but it can also greatly affect their quality of life and functional status [15, 46] . Although cancer-associated pain can be present at any time during the course of the disease, the frequency, severity and difficulty in controlling cancer pain tends to increase with advancing stages of cancer so that 75-90% of patients with metastatic or advanced-stage cancer will experience significant cancer-induced pain [10, 53, 55] .
Although cancer pain is common, our current understanding of the mechanisms that drive cancer pain are incomplete, as is our ability to fully control advanced cancer pain without significant unwanted side effects [6, 37, 40] . A number of factors have frustrated efforts to develop mechanism-based therapies to more effectively control chronic cancer pain. These include lack of animal models that mirror cancer pain that arises from different types of cancer [32, 38] , the poor correlation between tumor burden and the severity of pain [14, 30, 39] , and the lack of understanding as to how sensory and sympathetic nerve fibers that innervate the tumor-bearing organ change with disease progression.
These challenges notwithstanding, recent research has revealed that cancer pain is not simply due to inflammation at the tumor
